United States


EPOR.PK on OTC Markets Group

18 Oct 2016
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

EPIC Corp declares ninth consecutive quarterly stock dividend
Tuesday, 5 May 2015 09:00am EDT 

EPIC Corp:Declares ninth consecutive quarterly stock dividend on its Series A 5 pct Convertible Preferred Stock to preferred shareholders of record on June 22, which will be paid June 30.The dividend will be paid to preferred shareholders on the basis of 24 pct of the preferred shares owned.  Full Article

EPIC Corp declares first quarterly dividend
Tuesday, 9 Dec 2014 09:00am EST 

EPIC Corp:Declared it first quarterly dividend to common shareholders of record on Dec. 24 and payable on Dec. 31.The board of directors also declare the seventh consecutive quarterly stock dividend on its Series A 5 pct convertible preferred stock to preferred shareholders of record on Dec. 24 which will be paid Dec. 31.  Full Article

Epic acquires exclusive worldwide license to healthcare products valued at $1.95 mln
Monday, 17 Nov 2014 12:11pm EST 

Epic Corp:Acquires exclusive worldwide license to all the rights to the EPIC Fabric Healthcare Products in exchange for all its ownership rights to the AcuFABÂ trade name and design patent which was valued at $1.95 mln.Also receives a $1 mln License Fee from EPIC Medicor Corp for Marketing & Distribution rights.Receives an assignment of two sub license agreements, to RX Healthcare Systems, Ltd., a subsidiary of EPIC, and EPIC Medicor Corporation, an affiliated company.RX Healthcare received an exclusive for North America for consumer health care products.EPIC Medicor received an exclusive license for North America for medical market segments.Each license provides for a one time license fee of $1,000,000.Recently received the worldwide exclusive license and sub-licenses in exchange for any and all rights to the design patent, trademarks, pattern wheels and NDA.To pay a royalty of 5 pct on all product sales.  Full Article

No consensus analysis data available.